LIG3 as A Drug Target and Biomarker for Various Diseases (G3980)

Target Name: LIG3

NCBI ID: G3980

LIG3

LIG3 as A Drug Target and Biomarker for Various Diseases

LIG3 (polydeoxyribonucleotide synthase [ATP] 3) is a protein that plays a critical role in the process of DNA replication in all living organisms. It is a key enzyme in the replication of DNA in eukaryotic cells and is highly conserved across various species. LIG3 is highly expressed in various tissues and is involved in the regulation of DNA replication, repair, and other cellular processes.

Recent studies have identified LIG3 as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The high level of LIG3 expression in cancer cells has led to the idea that targeting LIG3 may be an effective way to treat these diseases.

One of the main reasons for the potential of LIG3 as a drug target is its involvement in the regulation of DNA replication. Cancer cells require an efficient DNA replication process in order to maintain their rapid growth and proliferation. However, the high levels of LIG3 expression in cancer cells can lead to an inability to replicate DNA properly, leading to issues with cell growth and division. By targeting LIG3, researchers hope to disrupt the replication of cancer cells, leading to a reduction in cell proliferation and a potential treatment for cancer.

Another potential mechanism by which LIG3 may be used as a drug target is its role in the regulation of cellular processes that are affected by various diseases, such as neurodegenerative diseases and autoimmune disorders. LIG3 has been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. In neurodegenerative diseases, such as Alzheimer's and Parkinson's, synaptic plasticity is often compromised, leading to the development of debilitating symptoms. By targeting LIG3, researchers hope to improve synaptic plasticity in these diseases, potentially leading to a more effective treatment.

In addition to its potential as a drug target, LIG3 has also been identified as a potential biomarker for various diseases. The high levels of LIG3 expression in tissues can make it a useful marker for diseases that affect the replication of DNA, such as cancer. Additionally, LIG3 has been shown to be involved in the regulation of cellular processes that are often affected by diseases, such as neurodegenerative diseases. By analyzing the levels of LIG3 in tissues, researchers may be able to use LIG3 as a diagnostic tool for these diseases and potentially identify new treatments.

Overall, LIG3 is a protein that has the potential to be a drug target and a biomarker for various diseases. The high levels of LIG3 expression in cancer cells, its involvement in the regulation of DNA replication, and its potential as a diagnostic tool make it an attractive target for researchers. Further studies are needed to fully understand the role of LIG3 in these diseases and to develop effective treatments.

Protein Name: DNA Ligase 3

Functions: Isoform 3 functions as heterodimer with DNA-repair protein XRCC1 in the nucleus and can correct defective DNA strand-break repair and sister chromatid exchange following treatment with ionizing radiation and alkylating agents. Isoform 1 is targeted to mitochondria, where it functions as DNA ligase in mitochondrial base-excision DNA repair (PubMed:10207110, PubMed:24674627)

The "LIG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets